Quest peddles BRCA test at a major medical conference despite Myriad lawsuit

Quest Diagnostics ($DGX) plans to debut its new BRCA-related cancer predictive test at a major medical conference this week, doing anything but keeping a low profile in the wake of rival Myriad Genetics' ($MYGN) patent infringement lawsuit. New Jersey-based Quest said it will showcase its newly launched BRCAvantage test at the 2013 San Antonio Breast Cancer Symposium from Dec. 10-14 in San Antonio, TX. Quest launched the test earlier this fall, following a U.S. Supreme Court decision over the summer that upheld some of Myriad's patent claims and vacated others, arguably opening the door to BRCA-related tests to compete against Myriad's BRCA-specific offerings. Quest preemptively sued to seek a decision on the matter, but Myriad has since sued Quest and many other competitors. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.